PubMed COVID-19 Clinical Care

Strict adherence to a diet is an essential pillar of long-term treatment for many inborn errors of metabolism (IEMs). Tools that educate patients about dietary management can positively condition adherence and prevent morbidity. We designed a free

Previous research has demonstrated that psychosocial resources are associated with elite athletes' perceived stress. However, these resources have mainly been studied separately. Using a person-oriented approach, this study aimed to identify

CONCLUSION: COVID-19 patients with systemic sclerosis had worse outcomes (i.e. higher composite endpoint of major adverse events) than those without systemic sclerosis. Further studies are needed to establish a better understanding of the

Prior to the COVID-19 pandemic, most of us had little to no experience with online teaching. With the realization that we would need to teach our students remotely during the pandemic, we needed to develop our online teaching skills and apply this

Outpatient Trials in the Covid-19 Era and BeyondA group of investigators had a meeting at the National Heart, Lung, and Blood Institute in May 2020 to discuss ways to decrease thrombotic complications among symptomatic outpatients with Covid-19. The

CONCLUSIONS: The mechanisms underlying oral AEFIs should be further investigated to promptly recognize oral manifestations and provide optimal management for people undergoing vaccination.

CONCLUSIONS: Our study demonstrated the effectiveness of the designed peptide added to the RBD to improve antigen immunostimulation by oral administration.

Oral Sabizabulin for High-Risk Adults with Covid-19Barnette et al. report on an interim analysis of a phase 3 randomized controlled trial of the orally available novel microtubule disruptor sabizabulin for severe Covid-19. They find a reduction in 60

CONCLUSIONS: Our study demonstrates that online consultation on labor analgesia was a good strategy during the COVID-19 pandemic and has the potential to be used in this format in the future.

BACKGROUND: In the interim report of this phase I/II randomized, placebo-controlled trial in Japanese adults, a two-dose primary series of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant nanoparticle spike protein [rS]; 50 µg Matrix-M) administered 21 days